Frontiers in Oncology (Sep 2022)

Celecoxib may be a viable treatment option for breast cancer patients not treated with chemotherapy

Randall E. Harris,
Randall E. Harris,
Judith A. Schwartzbaum

Affiliations

Randall E. Harris: College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, United States
Randall E. Harris: College of Public Health, The Ohio State University Wexner Medical Center, Columbus, OH, United States
Judith A. Schwartzbaum: College of Public Health, The Ohio State University Wexner Medical Center, Columbus, OH, United States

DOI: https://doi.org/10.3389/fonc.2022.958308
Journal volume & issue: Vol. 12

Abstract

No abstracts available.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal